Messenger

Merkle Launches Global Messaging Solution

Retrieved on: 
Thursday, March 21, 2024
Messenger, CRM, WWF, Growth, CXM, Partnership, Technology integration, Salesforce, SVP, Meta, Dentsu, Carat, AI, WhatsApp, Intelligence, Marketing, Brazing, William Grant & Sons, Adobe, Sales

With Intelligent Messaging, Merkle can create turnkey chat experiences, including across social and messaging platforms, delivering always-on conversational interactions throughout the entire customer journey.

Key Points: 
  • With Intelligent Messaging, Merkle can create turnkey chat experiences, including across social and messaging platforms, delivering always-on conversational interactions throughout the entire customer journey.
  • "Our new global solution, Intelligent Messaging, can be seamlessly integrated into existing plans, enabling brands to forge deeper connections with customers, enhance customer satisfaction, and generate lifetime value."
  • The Intelligent Messaging solution, part of Merkle's world-leading CRM & Messaging offering and incubated by the dentsu Integrated Solutions group, modularly connects across six key service areas:
    Intelligent Messaging Blueprint: Craft a tailored messaging strategy that shapes the customer experience for future-state marketing.
  • Dentsu and Meta recently joined forces to form a global Meta Messaging Alliance to provide dentsu, Merkle, and Meta clients with access to alpha and beta products across Meta Business Messaging platforms.

DNA Nanotechnology Market worth $24.3 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

Retrieved on: 
Thursday, March 21, 2024
Growth, Biotechnology, Danaher Corporation, NGS, Electronics, DNA, Research, Nanotechnology, Acquisition, Cancer, Messenger, Protein, Report, Medicine

The growing demand for the DNA nanotechnology market is fueled by the fact that DNA nanotechnology can transform industries as diverse as medicine, electronics, and materials research.

Key Points: 
  • The growing demand for the DNA nanotechnology market is fueled by the fact that DNA nanotechnology can transform industries as diverse as medicine, electronics, and materials research.
  • Significant factors fueling the market's growth include innovation, as mentioned earlier, potential, and the rising investment in nanotechnology research driven by the growth of DNA nanotechnology.
  • The North American DNA nanotechnology market is anticipated to record a maximum market share in terms of revenue.
  • Besides, Asia Pacific had a considerable market share in the market due to generating DNA nanotechnology solutions, which is encouraged by the expansion of nanotechnology, which stimulates collaboration between varied research groups and industries in this region.

DNA Nanotechnology Market worth $24.3 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

Retrieved on: 
Thursday, March 21, 2024
Growth, Biotechnology, Danaher Corporation, NGS, Electronics, DNA, Research, Nanotechnology, Acquisition, Cancer, Messenger, Protein, Agilent Technologies, Report, Medicine

The growing demand for the DNA nanotechnology market is fueled by the fact that DNA nanotechnology can transform industries as diverse as medicine, electronics, and materials research.

Key Points: 
  • The growing demand for the DNA nanotechnology market is fueled by the fact that DNA nanotechnology can transform industries as diverse as medicine, electronics, and materials research.
  • Significant factors fueling the market's growth include innovation, as mentioned earlier, potential, and the rising investment in nanotechnology research driven by the growth of DNA nanotechnology.
  • The North American DNA nanotechnology market is anticipated to record a maximum market share in terms of revenue.
  • Besides, Asia Pacific had a considerable market share in the market due to generating DNA nanotechnology solutions, which is encouraged by the expansion of nanotechnology, which stimulates collaboration between varied research groups and industries in this region.

Contract Research Organization (CRO) Market size to grow by USD 63.35 billion from 2024-2028, Market Growth at 12.61% CAGR expected during the forecast period, Technavio

Retrieved on: 
Wednesday, March 20, 2024
ChromeOS, Software as a service, Science, Chronic condition, Infection, Laboratory, Clinical trial, European, USD, Regulation, Obesity, Biotechnology, Risk, Diabetes, CNS, DSM-IV codes, ROW, Contract research organization, Compound annual growth rate, TB, PPD, Central nervous system disease, Neurology, Medicine, Medication, Clinical, Science 37, Research, Acquisition, Cancer, Drug development, HIV/AIDS, DCT, Growth, Cardiology, Software, Messenger, Behavior, PPD, Inc., Malaria, Lung compliance, Fine chemical

By geography, the global contract research organization (cro) market is segmented into North America, Europe, Asia, and Rest of World (ROW).

Key Points: 
  • By geography, the global contract research organization (cro) market is segmented into North America, Europe, Asia, and Rest of World (ROW).
  • The report provides actionable insights and estimates the contribution of all regions to the growth of the global contract research organization (cro) market.
  • Growth of the Contract Research Organization (CRO) Market industry across North America, Europe, Asia, and Rest of World (ROW)
    Gain instant access to 17,000+ market research reports.
  • The global mRNA synthesis raw material market size is estimated to grow by USD 776.45 million at a CAGR of 4.93% between 2023 and 2028.

Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer

Retrieved on: 
Monday, March 18, 2024
Novartis, NDA, Messenger, Greater China, HKEX, File, Vaccine, Amgen, Marketing, Lead, Pharmaceutical industry

SHANGHAI, March 17, 2024 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, today announced that the company has strengthened its management team with the appointments of Ms. Sandra Zeng as Chief Medical Officer and Mr. Rico Liang as Chief Product Officer.

Key Points: 
  • SHANGHAI, March 17, 2024 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, today announced that the company has strengthened its management team with the appointments of Ms. Sandra Zeng as Chief Medical Officer and Mr. Rico Liang as Chief Product Officer.
  • Ms. Sandra Zeng has been appointed Chief Medical Officer in charge of the clinical development team and cross function collaboration to bring more in-house developed and in-licensed innovative products in China.
  • Mr. Rico Liang has been appointed Chief Product Officer overseeing the Company's medical affairs and marketing departments.
  • We welcome Ms. Zeng and Mr. Liang as our new Chief Medical Officer and Chief Product Officer who bring to Everest decades of relevant global and China experience to help accelerate our strategic growth goals," said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines.

BioInnovation Institute welcomes innovative smartRNA project to Bio Studio program

Retrieved on: 
Thursday, March 14, 2024
Lykke, Epilepsy, EUR, KU Leuven, European Molecular Biology Laboratory, Haploinsufficiency, Genetics, Patient, Research, RNA, University of Washington, University, Messenger, Cancer, Laboratory, BII, Imperial College London, Student, EMBL, Monogenic, Aarhus University, University of Copenhagen, Intellectual property, Therapy, Molecular biology, DSM-IV codes, Disorder, Vaccine

Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.

Key Points: 
  • Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.
  • During the 3-year BII Bio Studio program, the objective of smartRNA is to deliver an in vitro proof-of-concept, a pseudo in vivo proof-of-principle, and in vitro benchmarking against established technologies.
  • Anja Mølhart Høg, Entrepreneur-in-Residence heading up the smartRNA project, added: "We are excited to welcome the smartRNA project to BII's Bio Studio program.
  • The Bio Studio program is a recently established BII program with the ambition to build and run a leading life science company creation facility in Europe.

BioInnovation Institute welcomes innovative smartRNA project to Bio Studio program

Retrieved on: 
Thursday, March 14, 2024
Lykke, Epilepsy, EUR, KU Leuven, European Molecular Biology Laboratory, Haploinsufficiency, Genetics, Patient, Research, RNA, University of Washington, University, Messenger, Cancer, Laboratory, BII, Imperial College London, Student, EMBL, Monogenic, Aarhus University, University of Copenhagen, Intellectual property, Therapy, Molecular biology, DSM-IV codes, Disorder, Vaccine

Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.

Key Points: 
  • Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.
  • During the 3-year BII Bio Studio program, the objective of smartRNA is to deliver an in vitro proof-of-concept, a pseudo in vivo proof-of-principle, and in vitro benchmarking against established technologies.
  • Anja Mølhart Høg, Entrepreneur-in-Residence heading up the smartRNA project, added: "We are excited to welcome the smartRNA project to BII's Bio Studio program.
  • The Bio Studio program is a recently established BII program with the ambition to build and run a leading life science company creation facility in Europe.

YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024

Retrieved on: 
Wednesday, March 13, 2024
LNP, Gene editing, Therapy, CMC, Messenger

SHANGHAI, March 13, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company pioneering in in vivo gene editing therapies, today announced participation in TIDES Asia 2024, March 19th to 21st, 2024, at the Westin Miyako Kyoto in Kyoto, Japan.

Key Points: 
  • SHANGHAI, March 13, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company pioneering in in vivo gene editing therapies, today announced participation in TIDES Asia 2024, March 19th to 21st, 2024, at the Westin Miyako Kyoto in Kyoto, Japan.
  • TIDES Asia , a conference in Asia that brings together discovery, clinical, delivery and CMC/manufacturing experts developing therapeutics/vaccines using modalities of Oligonucleotides, Peptides, mRNA and Genome Editing.
  • YolTech Therapeutics' representatives will bring latest advancements in in vivo gene editing technology and innovative LNP deliver system during the conference.
  • Sincerely invites partners, investors, and stakeholders to join the session at TIDES Asia 2024 to share views of our breakthroughs.

Modern Storage Media Partners with Scott Zucker on Self Storage Legal Monthly Minute

Retrieved on: 
Tuesday, March 12, 2024
Messenger, MSM, Partnership, Lauri, First, Book, Marketing, Zucker, Advertising

MSM's partnership with the Legal Monthly Minute will enable Zucker's pertinent, industry-focused legal information to be disseminated to self-storage owner-operators throughout the United States on a larger scale.

Key Points: 
  • MSM's partnership with the Legal Monthly Minute will enable Zucker's pertinent, industry-focused legal information to be disseminated to self-storage owner-operators throughout the United States on a larger scale.
  • "We have enjoyed working with Scott for many, many years and are overjoyed to formalize the integration of his Legal Monthly Minute into Messenger and the entire MSM platform," says Modern Storage Media Publisher Poppy Behrens.
  • Zucker's Legal Monthly Minute articles have been reprinted in numerous trade association newsletters and magazines, including MSM's Messenger.
  • "The Legal Monthly Minute was a way to share pertinent information in quick bites on a regular basis.

Sirnaomics will Present its Innovative Dual-Targeted GalNAc muRNA Programs in 2024 OPT Conference

Retrieved on: 
Tuesday, March 12, 2024
Gene, Congress, Oligonucleotide, Patient, RNA, Messenger, N-Acetylgalactosamine, Hepatocyte, Therapy, Múrna, RNA interference, Liver

Based on Sirnaomics' continued progress in targeting single genes with GalAheadTM mxRNA, Company is now pioneering GalAheadTM muRNA, a proprietary RNAi-based platform that allows for simultaneous downregulating of multiple genes.

Key Points: 
  • Based on Sirnaomics' continued progress in targeting single genes with GalAheadTM mxRNA, Company is now pioneering GalAheadTM muRNA, a proprietary RNAi-based platform that allows for simultaneous downregulating of multiple genes.
  • GalAheadTM muRNA, alike mxRNA employs GalNAc ligands, a clinically validated concept for RNAi trigger delivery to liver hepatocytes providing subsequent treatment of liver associated diseases.
  • The cleavage points allow for the muRNA after cellular delivery to break into two individual RNAi-triggers in the endo-lysosomal pathway.
  • In a different scenario, muRNA can simultaneously address two or more non-associated indications where patient populations have a considerable overlap.